Ontology highlight
ABSTRACT: Background
Visfatin is an adipokine that related with the inflammation in atherosclerosis and the destabilization of atherosclerotic plaque. The aim of this study was to observe the relationship between visfatin and major adverse cardiovascular events (MACEs) in acute myocardial infarction (AMI) patients.Methods
We enrolled a total of 238 patients (183 AMI and 55 control) who underwent coronary angiography. Patients with AMI were followed for an average of 19.3?months and 159 patients were finally included in the study.Results
It was observed patients with AMI had higher serum visfatin levels than controls. The total incidence of MACEs was 11.32% (18/159) in AMI patients. After calculation of the Youden index, the best cut-off value of visfatin on the curve of receiver-operating characteristic was 8.799?ng/mL for predicting the occurrence of MACEs. The occurrence of MACEs was elevated in high-visfatin group (?8.799?ng/mL) compared with low-visfatin group (?8.799?ng/mL). The time to MACEs was correlated with visfatin (HR?=?1.235, 95%CI 1.051-1.451, P?=?0.01) and high-visfatin group had an earlier time to MACEs and a shorter time of cumulative survival.Conclusions
Increased serum visfatin levels were observed in AMI patients, and correlated with an earlier onset and higher incidence of MACEs.
SUBMITTER: Zheng M
PROVIDER: S-EPMC7275306 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
Zheng Meifan M Lu Nan N Ren Meixia M Chen Haifeng H
BMC cardiovascular disorders 20200605 1
<h4>Background</h4>Visfatin is an adipokine that related with the inflammation in atherosclerosis and the destabilization of atherosclerotic plaque. The aim of this study was to observe the relationship between visfatin and major adverse cardiovascular events (MACEs) in acute myocardial infarction (AMI) patients.<h4>Methods</h4>We enrolled a total of 238 patients (183 AMI and 55 control) who underwent coronary angiography. Patients with AMI were followed for an average of 19.3 months and 159 pat ...[more]